Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment by targeting dual antigens, addressing tumor heterogeneity. With ...

Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced ...

Dr. Nooka provides comprehensive guidance on bispecific antibody safety management, emphasizing the predictable chronology of ...

Merck MRK announced that the European Commission (EC) has approved Enflonsia (clesrovimab) for the prevention of respiratory ...

The immune system's B cells create antibodies that can mount a response against just about anything—either destroying a ...

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...

Antibody humanization involves modifying antibodies from non-human sources, such as mice, to decrease their immunogenicity in human applications. While mouse monoclonal antibodies are specific, they ...

Mezagitamab is a fully human IgG1 monoclonal antibody that targets CD38, which is highly expressed on the surface of plasma ...

Every winter, respiratory syncytial virus sends tens of thousands of U.S. infants to the hospital, filling pediatric ICU beds ...

Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer patient and survivor artwork, which will be featured in an innovative project linking ...